Strategies to Improve γδTCRs Engineered T-cell Therapies for the Treatment of Solid Malignancies

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jul 13

PMID 37441064

Authors

A D Meringa

P Hernandez-Lopez

A Cleven

M de Witte

T Straetemans

J Kuball

D X Beringer

Z Sebestyen

Affiliations

Soon will be listed here.

References

Supimon K, Sangsuwannukul T, Sujjitjoon J, Chieochansin T, Junking M, Yenchitsomanus P . Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells. Cytotherapy. 2022; 25(2):148-161. DOI: 10.1016/j.jcyt.2022.10.006. View

Pellegrino M, Del Bufalo F, De Angelis B, Quintarelli C, Caruana I, de Billy E . Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy. Cells. 2020; 10(1). PMC: 7824126. DOI: 10.3390/cells10010014. View

Cazzetta V, Bruni E, Terzoli S, Carenza C, Franzese S, Piazza R . NKG2A expression identifies a subset of human Vδ2 T cells exerting the highest antitumor effector functions. Cell Rep. 2021; 37(3):109871. DOI: 10.1016/j.celrep.2021.109871. View

Majzner R, Ramakrishna S, Yeom K, Patel S, Chinnasamy H, Schultz L . GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022; 603(7903):934-941. PMC: 8967714. DOI: 10.1038/s41586-022-04489-4. View

Dadi S, Chhangawala S, Whitlock B, Franklin R, Luo C, Oh S . Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells. Cell. 2016; 164(3):365-77. PMC: 4733424. DOI: 10.1016/j.cell.2016.01.002. View

Zakeri N, Hall A, Swadling L, Pallett L, Schmidt N, Diniz M . Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nat Commun. 2022; 13(1):1372. PMC: 8927126. DOI: 10.1038/s41467-022-29012-1. View

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

Kowolik C, Topp M, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N . CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006; 66(22):10995-1004. DOI: 10.1158/0008-5472.CAN-06-0160. View

Liu Y, Liu G, Wang J, Zheng Z, Jia L, Rui W . Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021; 13(586). DOI: 10.1126/scitranslmed.abb5191. View

10.

Hoogi S, Eisenberg V, Mayer S, Shamul A, Barliya T, Cohen C . A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. J Immunother Cancer. 2019; 7(1):243. PMC: 6734436. DOI: 10.1186/s40425-019-0721-y. View

11.

Xu Y, Xiang Z, Alnaggar M, Kouakanou L, Li J, He J . Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol Immunol. 2020; 18(2):427-439. PMC: 8027668. DOI: 10.1038/s41423-020-0515-7. View

12.

Junttila M, de Sauvage F . Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; 501(7467):346-54. DOI: 10.1038/nature12626. View

13.

Dahmani A, Delisle J . TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. Cancers (Basel). 2018; 10(6). PMC: 6025055. DOI: 10.3390/cancers10060194. View

14.

Lanitis E, Poussin M, Klattenhoff A, Song D, Sandaltzopoulos R, June C . Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2014; 1(1):43-53. PMC: 3881605. DOI: 10.1158/2326-6066.CIR-13-0008. View

15.

Brigl M, Brenner M . CD1: antigen presentation and T cell function. Annu Rev Immunol. 2004; 22:817-90. DOI: 10.1146/annurev.immunol.22.012703.104608. View

16.

Gao T, Chen Y . Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism. Annu Rev Chem Biomol Eng. 2022; 13:193-216. DOI: 10.1146/annurev-chembioeng-092120-092914. View

17.

Tran E, Chinnasamy D, Yu Z, Morgan R, Lee C, Restifo N . Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013; 210(6):1125-35. PMC: 3674706. DOI: 10.1084/jem.20130110. View

18.

Fournie J, Sicard H, Poupot M, Bezombes C, Blanc A, Romagne F . What lessons can be learned from γδ T cell-based cancer immunotherapy trials?. Cell Mol Immunol. 2012; 10(1):35-41. PMC: 4003170. DOI: 10.1038/cmi.2012.39. View

19.

van Rhijn I, Le Nours J . CD1 and MR1 recognition by human γδ T cells. Mol Immunol. 2021; 133:95-100. PMC: 8075093. DOI: 10.1016/j.molimm.2020.12.008. View

20.

Willcox C, Pitard V, Netzer S, Couzi L, Salim M, Silberzahn T . Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat Immunol. 2012; 13(9):872-9. DOI: 10.1038/ni.2394. View